Immune dysfunction is a cause and consequence of critical illness. Immune checkpoint inhibitors can improve the care of patients with malignancy, however, they also have immune-related adverse reactions. In both trauma and sepsis, acquired immune deficiency can be a consequence of critical illness that can put patients at further risk of complications, particularly hospital-acquired infections. Immune modulation and stimulation are emerging as strategies to improve patient outcomes in illnesses of infective and inflammatory aetiologies, these include but are not limited to, glucocorticoids, recombinant interleukins, interleukin receptor antagonists.
With this Research Topic, we would like to collect the recent advances in the identification of patients at risk of critical illness as a result of immune modulation.
We would like to describe the state of the art in monitoring immune dysfunctions in critical illness, notably in trauma and sepsis. We welcome studies investigating the relationship between persistent inflammation and long-term outcome in critical illness. We welcome studies describing the emerging use of immune modulation for the treatment of critical illness including glucocorticoids, recombinant interleukins, interleukin receptor antagonism, GM-CSF, and type II interferons, and studies describing the role of nutrition and the microbiome on modifying the immune response.
Authors are encouraged to submit manuscripts on the following themes:
- Immune checkpoint inhibitors and critical illness
- Monocyte dysfunction in critical illness
- Neutrophil dysfunction in critical illness
- Lymphocyte dysfunction in critical illness
- Monitoring of immune dysfunction in sepsis and following trauma
- Immune modulation in sepsis/pneumonia
- Immune modulation in rheumatological crises
- The role of nutrition and the microbiome in modifying the immune response
- The role of cellular metabolism in immunomodulation
- Persistent inflammation and long-term outcomes
Immune dysfunction is a cause and consequence of critical illness. Immune checkpoint inhibitors can improve the care of patients with malignancy, however, they also have immune-related adverse reactions. In both trauma and sepsis, acquired immune deficiency can be a consequence of critical illness that can put patients at further risk of complications, particularly hospital-acquired infections. Immune modulation and stimulation are emerging as strategies to improve patient outcomes in illnesses of infective and inflammatory aetiologies, these include but are not limited to, glucocorticoids, recombinant interleukins, interleukin receptor antagonists.
With this Research Topic, we would like to collect the recent advances in the identification of patients at risk of critical illness as a result of immune modulation.
We would like to describe the state of the art in monitoring immune dysfunctions in critical illness, notably in trauma and sepsis. We welcome studies investigating the relationship between persistent inflammation and long-term outcome in critical illness. We welcome studies describing the emerging use of immune modulation for the treatment of critical illness including glucocorticoids, recombinant interleukins, interleukin receptor antagonism, GM-CSF, and type II interferons, and studies describing the role of nutrition and the microbiome on modifying the immune response.
Authors are encouraged to submit manuscripts on the following themes:
- Immune checkpoint inhibitors and critical illness
- Monocyte dysfunction in critical illness
- Neutrophil dysfunction in critical illness
- Lymphocyte dysfunction in critical illness
- Monitoring of immune dysfunction in sepsis and following trauma
- Immune modulation in sepsis/pneumonia
- Immune modulation in rheumatological crises
- The role of nutrition and the microbiome in modifying the immune response
- The role of cellular metabolism in immunomodulation
- Persistent inflammation and long-term outcomes